Equity Profile

AMGN

Amgen Inc.

Health CareBiotechnology$226.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Amgen Inc. is a biotechnology company that focuses on developing innovative therapies to treat serious illnesses....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and how well the company is managing its costs and revenues.

$5.62

Revenue

Total revenue shows the company's ability to generate sales and is critical for assessing overall business health.

$9.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Amgen Inc. is a biotechnology company that focuses on developing innovative therapies to treat serious illnesses. Operating in the health care sector, Amgen plays a crucial role in advancing medical science and improving patient outcomes through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1 2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. The stock reacted positively, gaining 2.43% the following day.

Management Promises & Guidance

Continue to focus on innovative drug development.
Maintain strong cost management strategies.
Expand market presence in key therapeutic areas.

Expectations

Wall Street Expectations

Analysts expect Amgen to report solid earnings this quarter, with a consensus EPS of $5.62. The company has a strong track record of beating earnings estimates, which could set high expectations.

Bull Case

If Amgen exceeds EPS expectations and shows strong revenue growth, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$5.62

Earnings per share is a key indicator of profitability and how well the company is managing its costs and revenues.

Revenue

$9.4B

Total revenue shows the company's ability to generate sales and is critical for assessing overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amgen's EPS exceed the consensus estimate of $5.62?

A strong EPS could reinforce investor confidence and lead to a positive stock reaction.

What guidance will management provide for future revenue growth?

Future revenue guidance will be critical for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amgen's ability to drive revenue growth through new product launches, which could lead to a significant earnings surprise.

Supporting Evidence

Amgen has consistently beaten EPS estimates in the past, indicating strong operational performance.

The options market is pricing a move of 3.48%, suggesting that investors are bracing for volatility.

Recent insider buying activity could signal confidence in the company's future prospects.

Key Risk

If Amgen's new product sales exceed expectations, it could significantly alter the earnings outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on Amgen's ability to meet or exceed earnings expectations and provide positive guidance.

Bull Confirmed If

An EPS of $5.75 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a moderate move around the earnings report, suggesting some uncertainty among investors.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats earnings expectations, history suggests the stock could rise by about 1.09% on average, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should Amgen miss expectations, history indicates a potential drop of around 0.15%, which could lead to increased skepticism about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-FLMaria Elvira SalazarRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and their effectiveness.
3Insights into market trends affecting Amgen's therapeutic areas.
4Guidance on future revenue growth and market expansion plans.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Amgen Inc. is a biotechnology company that focuses on developing innovative therapies to treat serious illnesses....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and how well the company is managing its costs and revenues.

$5.62

Revenue

Total revenue shows the company's ability to generate sales and is critical for assessing overall business health.

$9.4B

Wall Street expectations, options signals, track record, and call prep available with Pro.

AMGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+10.24%

Avg Stock Reaction

-0.15%

Last Quarter Recap

In Q1 2026, Amgen reported an EPS of $5.15, exceeding expectations by 8.88%. The stock reacted positively, gaining 2.43% the following day.

Management Promises & Guidance

Continue to focus on innovative drug development.
Maintain strong cost management strategies.
Expand market presence in key therapeutic areas.

Expectations

Wall Street Expectations

Analysts expect Amgen to report solid earnings this quarter, with a consensus EPS of $5.62. The company has a strong track record of beating earnings estimates, which could set high expectations.

Bull Case

If Amgen exceeds EPS expectations and shows strong revenue growth, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$5.62

Earnings per share is a key indicator of profitability and how well the company is managing its costs and revenues.

Revenue

$9.4B

Total revenue shows the company's ability to generate sales and is critical for assessing overall business health.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amgen's EPS exceed the consensus estimate of $5.62?

A strong EPS could reinforce investor confidence and lead to a positive stock reaction.

What guidance will management provide for future revenue growth?

Future revenue guidance will be critical for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amgen's ability to drive revenue growth through new product launches, which could lead to a significant earnings surprise.

Supporting Evidence

Amgen has consistently beaten EPS estimates in the past, indicating strong operational performance.

The options market is pricing a move of 3.48%, suggesting that investors are bracing for volatility.

Recent insider buying activity could signal confidence in the company's future prospects.

Key Risk

If Amgen's new product sales exceed expectations, it could significantly alter the earnings outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on Amgen's ability to meet or exceed earnings expectations and provide positive guidance.

Bull Confirmed If

An EPS of $5.75 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $5.50 would confirm the bear case and raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±3.48%

Historical Avg

±1.1%

Pricing rich

The options market is pricing in a moderate move around the earnings report, suggesting some uncertainty among investors.

Options are pricing ±3.5% while AMGN has averaged ±1.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

24.6%

Calls (248K)P/C Ratio: 0.58Puts (419K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amgen beats earnings expectations, history suggests the stock could rise by about 1.09% on average, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should Amgen miss expectations, history indicates a potential drop of around 0.15%, which could lead to increased skepticism about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$15,001.00–$50,000.00

disclosed dollar ranges

Most Active Members

R-FLMaria Elvira SalazarRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and their effectiveness.
3Insights into market trends affecting Amgen's therapeutic areas.
4Guidance on future revenue growth and market expansion plans.
5Responses to analyst questions regarding competitive pressures in the biotechnology sector.